The coronavirus disease 2019(COVID-19)global public health emergency,has exposed the fragility of health systems.Access to healthcare became a scarce commodity as healthcare providers and resource-poor populations bec...The coronavirus disease 2019(COVID-19)global public health emergency,has exposed the fragility of health systems.Access to healthcare became a scarce commodity as healthcare providers and resource-poor populations became victims of the novel corona virus.Therefore,this study focuses on Africa’s readiness to integrate telemedicine into the weak health systems and its adoption may help alleviate poor healthcare and poverty after COVID-19.We conducted a narrative review through different search strategies in Scopus on January 20,2021,to identify available literature reporting implementation of various telemedicine modes in Africa from January 1,2011 to December 31,2020.We summarized 54 studies according to geographies,field,and implementation methods.The results show a willingness to adopt telemedicine in the resource-poor settings and hard-to-reach populations,which will bring relief to the inadequate healthcare systems and alleviate poverty of those who feel the burden of healthcare cost the most.With adequate government financing,telemedicine promises to enhance the treating of communicable and non-communicable diseases as well as support health infrastructure.It can also alleviate poverty among vulnerable groups and hard-to-reach communities in Africa with adequate government financing.However,given the lack of funding in Africa,the challenges in implementing telemedicine require global and national strategies before it can yield promising results.This is especially true in regards to alleviating the multidimensionality of poverty in post-COVID-19 Africa.展开更多
In the context of dual economic structure,there occurs shift of numerous rural surplus labors in China. As a special group lingering about in the edges of urban and rural areas,the new generation farmers become a hot ...In the context of dual economic structure,there occurs shift of numerous rural surplus labors in China. As a special group lingering about in the edges of urban and rural areas,the new generation farmers become a hot spot of research. How to help them smoothly become successors of China's agricultural modernization construction is a focus of academic circles. Based on literature review,this paper analyzed connotation of development capability of new generation farmers from agricultural modernization,thinking ability construction,system and policy,and new farmers. Finally,it came up with prospect for development of new generation farmers.展开更多
We aimed to assess the tolerability and efficacy of finotonlimab(an anti-programmed cell death protein-1 antibody)in combination with SCT510,a bevacizumab biosimilar,versus sorafenib in unresectable advanced HCC.This ...We aimed to assess the tolerability and efficacy of finotonlimab(an anti-programmed cell death protein-1 antibody)in combination with SCT510,a bevacizumab biosimilar,versus sorafenib in unresectable advanced HCC.This randomized phase 2 and 3 study(ClinicalTrials.gov,NCT04560894;Chinadrugtrials.org.cn,CTR20201976 and CTR20201974)was performed at 67 hospitals in China.HCC patients(n=398)were included between 11 November 2020 and 28 September 2022.In phase 2,patients received intravenous finotonlimab(200 mg every 3 weeks)combined with SCT510(15 mg/kg every 3 weeks).In phase 3,346 patients were randomized(2:1)to either the finotonlimab plus SCT510(dual-agent)group or the sorafenib group.The median follow-up time for the dual-agent therapy and sorafenib groups was 19.9 and 19.0 months,respectively.Median PFS,assessed by BICR according to RECIST 1.1,was significantly longer in the dual-agent group(7.1 months[95%confidence intervals{CI}:6.1,8.4])than in the sorafenib group(2.9 months[95%CI:2.8,4.1];stratified hazard ratio[HR]:0.5,95%CI:0.38,0.65,p<0.0001).Median OS was also significantly longer in patients receiving finotonlimab plus SCT510(22.1 months[18.6,not available])than in those receiving sorafenib(14.2 months[95%CI:10.2,15.8];HR:0.60[95%CI:0.44,0.81],p<0.0008).Finotonlimab in combination with bevacizumab demonstrated favorable efficacy,in comparison to sorafenib,as a first-line treatment for unresectable HCC,with a manageable safety profile.展开更多
文摘The coronavirus disease 2019(COVID-19)global public health emergency,has exposed the fragility of health systems.Access to healthcare became a scarce commodity as healthcare providers and resource-poor populations became victims of the novel corona virus.Therefore,this study focuses on Africa’s readiness to integrate telemedicine into the weak health systems and its adoption may help alleviate poor healthcare and poverty after COVID-19.We conducted a narrative review through different search strategies in Scopus on January 20,2021,to identify available literature reporting implementation of various telemedicine modes in Africa from January 1,2011 to December 31,2020.We summarized 54 studies according to geographies,field,and implementation methods.The results show a willingness to adopt telemedicine in the resource-poor settings and hard-to-reach populations,which will bring relief to the inadequate healthcare systems and alleviate poverty of those who feel the burden of healthcare cost the most.With adequate government financing,telemedicine promises to enhance the treating of communicable and non-communicable diseases as well as support health infrastructure.It can also alleviate poverty among vulnerable groups and hard-to-reach communities in Africa with adequate government financing.However,given the lack of funding in Africa,the challenges in implementing telemedicine require global and national strategies before it can yield promising results.This is especially true in regards to alleviating the multidimensionality of poverty in post-COVID-19 Africa.
基金Supported by Project of National Social Science Foundation(13BJL061)Innovation Program for Postgraduate
文摘In the context of dual economic structure,there occurs shift of numerous rural surplus labors in China. As a special group lingering about in the edges of urban and rural areas,the new generation farmers become a hot spot of research. How to help them smoothly become successors of China's agricultural modernization construction is a focus of academic circles. Based on literature review,this paper analyzed connotation of development capability of new generation farmers from agricultural modernization,thinking ability construction,system and policy,and new farmers. Finally,it came up with prospect for development of new generation farmers.
基金National Science and Technology Major Projects of China[2019ZX09732-001]provided funding.
文摘We aimed to assess the tolerability and efficacy of finotonlimab(an anti-programmed cell death protein-1 antibody)in combination with SCT510,a bevacizumab biosimilar,versus sorafenib in unresectable advanced HCC.This randomized phase 2 and 3 study(ClinicalTrials.gov,NCT04560894;Chinadrugtrials.org.cn,CTR20201976 and CTR20201974)was performed at 67 hospitals in China.HCC patients(n=398)were included between 11 November 2020 and 28 September 2022.In phase 2,patients received intravenous finotonlimab(200 mg every 3 weeks)combined with SCT510(15 mg/kg every 3 weeks).In phase 3,346 patients were randomized(2:1)to either the finotonlimab plus SCT510(dual-agent)group or the sorafenib group.The median follow-up time for the dual-agent therapy and sorafenib groups was 19.9 and 19.0 months,respectively.Median PFS,assessed by BICR according to RECIST 1.1,was significantly longer in the dual-agent group(7.1 months[95%confidence intervals{CI}:6.1,8.4])than in the sorafenib group(2.9 months[95%CI:2.8,4.1];stratified hazard ratio[HR]:0.5,95%CI:0.38,0.65,p<0.0001).Median OS was also significantly longer in patients receiving finotonlimab plus SCT510(22.1 months[18.6,not available])than in those receiving sorafenib(14.2 months[95%CI:10.2,15.8];HR:0.60[95%CI:0.44,0.81],p<0.0008).Finotonlimab in combination with bevacizumab demonstrated favorable efficacy,in comparison to sorafenib,as a first-line treatment for unresectable HCC,with a manageable safety profile.
